Sprouty2 loss‐induced IL6 drives castration‐resistant prostate cancer through scavenger receptor B1
Abstract Metastatic castration‐resistant prostate cancer (mCRPC) is a lethal form of treatment‐resistant prostate cancer and poses significant therapeutic challenges. Deregulated receptor tyrosine kinase (RTK) signalling mediated by loss of tumour suppressor Sprouty2 (SPRY2) is associated with treat...
Main Authors: | Rachana Patel, Janis Fleming, Ernest Mui, Carolyn Loveridge, Peter Repiscak, Arnaud Blomme, Victoria Harle, Mark Salji, Imran Ahmad, Katy Teo, Freddie C Hamdy, Ann Hedley, Niels van den Broek, Gillian Mackay, Joanne Edwards, Owen J Sansom, Hing Y Leung |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-04-01
|
Series: | EMBO Molecular Medicine |
Subjects: | |
Online Access: | https://doi.org/10.15252/emmm.201708347 |
Similar Items
-
The evolution of the class A scavenger receptors
by: Whelan Fiona J, et al.
Published: (2012-11-01) -
Alpha-Fetoprotein Binding Mucin and Scavenger Receptors: An Available Bio-Target for Treating Cancer
by: Bo Lin, et al.
Published: (2021-02-01) -
Ailanthone: a new potential drug for castration-resistant prostate cancer
by: Shihong Peng, et al.
Published: (2017-03-01) -
Mechanisms behind growth of castration-resistant prostate cancer bone metastases
by: Jernberg, Emma
Published: (2013) -
The Evolution of the Scavenger Receptor Cysteine-Rich Domain of the Class A Scavenger Receptors
by: Nicholas eYap, et al.
Published: (2015-07-01)